Drug intelligence / Profile preview

ENP-501

Development stage: Phase 2
Lead developer: N-Fold
Administration: Unknown

Overview

ENP-501 is an investigational drug being evaluated for the treatment of **peanut allergy**. It is currently in Phase 1/2 clinical trials designed to assess safety and clinical activity in both healthy individuals and participants with an established peanut allergy. The mechanism of action and the specific nature of ENP-501 (such as biologic, small molecule, or other) are not detailed in public records, but the trial design includes evaluation of immunologic endpoints including IgE and IgG4 specific to peanut proteins such as Ara h 1, Ara h 2, and Ara h 3. The study also includes double-blind placebo-controlled food challenges (DBPCFC) to assess clinical tolerance to peanut protein in treated participants. ENP-501 is being developed by N-Fold.

Other names: ENP-501ENP501ENP 501

Beyond the preview

Go deeper on ENP-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENP-501.

Explore the full profile